Evidence map›Paper›PMID 39225725›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Quantification of Gremlin 1 throughout the tumor stroma using whole slide imaging and its clinicopathological significance in gastric cancer.

Takumi Kitaoka, Kenji Harada, Shingo Sakashita, Motohiro Kojima, Tetsuro Taki, Takeshi Kuwata, Takahiro Kinoshita, Mitsuru Futakuchi, Genichiro Ishii, Naoya Sakamoto

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takumi KitaokaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Kenji HaradaDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Shingo SakashitaDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Motohiro KojimaDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Tetsuro TakiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi KuwataDepartment of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
Takahiro KinoshitaDepartment of Gastric Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Mitsuru FutakuchiDepartment of Pathology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Genichiro IshiiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Naoya SakamotoDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan. naosakam@east.ncc.go.jp.ORCID http://orcid.org/0000-0001-6273-0189

Funding

Japan Society for the Promotion of Science 21H02931Japan Society for the Promotion of Science 22K09661
6 · The paper itself

Abstract

Gremlin 1 (GREM1) is an antagonist of bone morphogenetic protein (BMP). GREM1 is expressed in the stromal cells of various carcinomas and promotes tumor progression by suppressing BMP signaling. We designed this study to establish an evaluation strategy for GREM1 expression, focusing on the tumor stroma, and to examine its clinicopathological significance in gastric cancer (GC) progression. We employed RNA in situ hybridization (ISH) to evaluate the prognostic value of GREM1 expression in a cohort of 104 surgically resected GC cases and assessed ISH scores according to previous reports. GREM1 expression was observed in tumor stromal cells, including fibroblasts. We defined GREM1-positive cells as those expressing ISH score ≥ 3 and quantified the number of GREM1-positive cells using image analysis software. We examined the relationship between the number of GREM1-positive cells in the tumor stroma and clinicopathological features. The number of GREM1-positive cells per tumor stroma ranged from 0 to 714.7 cells/mm

Indexed as

Biomarkers, TumorIntercellular Signaling Peptides and ProteinsStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansIn Situ HybridizationKaplan-Meier EstimateMaleMiddle AgedPrognosisStromal CellsTumor MicroenvironmentBiomarkers, TumorGREM1 protein, humanIntercellular Signaling Peptides and ProteinsGastric cancerGremlin 1 (GREM1)In situ hybridizationMicroenvironmentTumor stromal cell

Identifiers

PMID39225725

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.